Harpoon Therapeutics Inc. (Nasdaq: HARP)

https://www.harpoontx.com

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, PhD, a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel antibody-based drug discovery platform called TriTAC™ (tri-specific T-cell activating construct) to unleash the targeted cell-killing properties of a patient’s own immune system through T-cell activation. This approach has been optimized to penetrate tissues and extend serum exposure, and has the potential to address a broad range of cancers, including solid tumors, and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC™ biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial in 2018. *

	Start	2015-01-01 established
	Group	Merck (US) (MSD) (Group)
	Industry	TriTAC™ imunno-oncology platform (tri-specific T-cell activating construct immuno-oncology platform)
	Industry 2	HPN328 (Harpoon Therapeutics)
	Person	Eastland, Julie E. (Harpoon Therapeutics 202401 CEO before BioClin Tx + Cascadian Tx + VLST Corp + Dendreon + Amgen)
	Person 2	Bäuerle, Patrick (MPM Capital 201710 Managing Director formerly Micromet)

	Region	South San Francisco, CA
	Country	United States (USA)
	Street	4000 Shoreline Court Suite 250
	City	94080 South San Francisco, CA
	Tel	+1-650-443-7400
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Harpoon Therapeutics, Inc.. (5/25/17). "Press Release: Harpoon Therapeutics Announces Completion of $45M Series B Financing". South San Francisco, CA.

		Record changed: 2024-01-19